. Author manuscript; available in PMC: 2017 Nov 1.

Published in final edited form as: Urol Oncol. 2016 Sep 14;34(11):484.e19–484.e25. doi: 10.1016/j.urolonc.2016.05.033

Table 2. Multivariable Adjusted Comparison of BCG Connaught to BCG TICE: All Patients.

		BCG Connaught (n=957) N, (%)	BCG Tice (n=1142) N, (%)	Hazard Ratio (95% CI)	P value	P value Interaction with Maintenance
Recurrence	No	518 (54.1)	517 (45.3)	1.18 (1.00 – 1.39)	0.047	< 0.001
Recurrence	Yes	439 (45.9)	625 (54.7)	1.18 (1.00 – 1.39)	0.047	< 0.001
Progression	No	779 (81.4)	940 (82.3)	1.08 (0.84 – 1.39)	0.55	0.16
Progression	Yes	178 (18.6)	202 (17.7)	1.08 (0.84 – 1.39)	0.55	0.16
Survival	Alive	713 (74.5)	868 (76.0)	1.02 (0.81 – 1.28)	0.87	0.13
Survival	Dead	244 (25.5)	274 (24.0)	1.02 (0.81 – 1.28)	0.87	0.13
Death Bladder Cancer	No	864 (90.3)	1054 (92.3)	0.73 (0.50 – 1.06)	0.10	0.12
Death Bladder Cancer	Yes	93 (9.7)	88 (7.7)	0.73 (0.50 – 1.06)	0.10	0.12

HR > 1 favors Connaught, HR < 1 favors TICE